Intervacc

Stockholm, February 13, 2025 - Intervacc AB (publ) today announces that the variation application previously submitted to the European Medicines Agency (EMA) has now been approved. The approval concerns improved methods and processes which are a part of the manufacturing process for Strangvac, the company's vaccine against equine strangles.

The approval from EMA marks an important milestone in Intervacc's efforts to ensure increased flexibility and stability in production processes. The new processes have been developed over a period of approximately 1.5 years and aim to provide greater flexibility and stability in manufacturing.

"This is a significant milestone for Intervacc which means we can intensify our sales efforts," says Jonas Sohlman, CEO of Intervacc.

The improved processes have already been implemented in the production carried out during the autumn, and the vaccine has been made available for sale through a special procedure, Special Batch Release, in markets where it has been launched.

For more information please contact:  

Jonas Sohlman, CEO

Phone: +46 (0)8 120 10 600

E-mail: jonas.sohlman@intervacc.se

The information was submitted for publication, through the agency of the contact person set out above on February 13, 2025, 18.45 CET.

About Intervacc

Intervacc AB is a Swedish company within animal health developing vaccines for animals. The Company develops and sells vaccines against animal diseases based on the proprietary technology platform with fused recombinant proteins. The Intervacc share is on listed the Nasdaq First North Growth Market.

Contact information for Certified Adviser

Eminova Fondkommission AB

E-mail: adviser@eminova.se, Phone: +46 (0)8 - 684 211 10